Shanghai Huilun Pharmaceutical Co. Ltd. has identified new angiotensin AT2 receptor antagonists potentially useful for the treatment of neuropathic pain.
Chengdu Shibeikang Biological Medicine Technology Co. Ltd. has patented new platelet adhesion inhibitors reported to be useful for the treatment of cardiovascular and cerebrovascular disorders.
A patent from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. has divulged new antibody-drug conjugates comprising antibodies covalently linked to N-myristoyltransferase 1 (NMT1) inhibitors for potential use in the treatment of cancer.
Wuhan Createrna Science and Technology Co. Ltd. has synthesized new cyclobutenedione compounds acting as C-C chemokine receptor type 6 (CCR6) antagonists potentially useful for the treatment of inflammatory bowel disease, allergy, dry eye, psoriasis, rheumatoid arthritis and multiple sclerosis.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has disclosed new dual proprotein convertase subtilisin/kexin-type 9 (PCSK9) and lipoprotein(a) (Lp[a])-targeting agents potentially useful for the treatment of hypercholesterolemia.
Sichuan Huiyu Pharmaceuticals Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have patented new Son of sevenless homolog 1 (SOS1) inhibitors potentially useful for the treatment of cancer and Noonan syndrome.
Iteos Belgium SA has synthesized new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 inhibitors potentially useful for the treatment of cancer.
Ensem Therapeutics Inc. has disclosed new tetracyclic GTPase KRAS mutant inhibitors, particularly G12V mutant inhibitors, potentially useful for the treatment of cancer.
RSS
